Profile data is unavailable for this security.
About the company
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
- Revenue in USD (TTM)169.14m
- Net income in USD-33.41m
- Incorporated2006
- Employees315.00
- LocationHarrow Inc102 WOODMONT BLVD, SUITE 610NASHVILLE 37215United StatesUSA
- Phone+1 (615) 733-4731
- Fax+1 (858) 345-1745
- Websitehttps://www.harrow.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phibro Animal Health Corp | 1.05bn | 17.41m | 962.37m | 1.94k | 55.35 | 3.72 | 17.92 | 0.9194 | 0.4293 | 0.4293 | 25.82 | 6.38 | 1.08 | 2.60 | 6.75 | 539,568.10 | 1.80 | 3.93 | 2.20 | 4.90 | 31.47 | 31.18 | 1.66 | 3.77 | 1.69 | 2.20 | 0.6472 | 56.45 | 4.07 | 4.21 | -92.59 | -46.35 | 6.65 | 0.8548 |
| Collegium Pharmaceutical Inc | 599.25m | 88.59m | 980.73m | 197.00 | 15.21 | 4.18 | 4.14 | 1.64 | 2.00 | 2.00 | 13.05 | 7.27 | 0.4261 | 6.25 | 2.92 | 3,041,853.00 | 6.30 | 2.79 | 9.38 | 4.80 | 62.36 | 50.88 | 14.78 | 5.16 | 0.8832 | 3.94 | 0.7873 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 138.16m | -72.58m | 1.12bn | 154.00 | -- | 15.04 | -- | 8.12 | -0.7894 | -0.7894 | 1.48 | 0.775 | 0.7647 | 1.04 | 6.38 | 897,142.90 | -40.17 | -40.21 | -54.87 | -47.99 | 91.92 | -- | -52.53 | -374.75 | 2.60 | -6.11 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 555.46m | -8.77m | 1.17bn | 642.00 | -- | 2.90 | 22.76 | 2.11 | -0.4489 | -0.4489 | 28.67 | 20.44 | 0.5102 | 1.75 | 2.96 | 865,196.30 | -0.6514 | -2.83 | -0.7654 | -3.35 | 59.79 | 60.18 | -1.28 | -6.15 | 1.97 | 0.7018 | 0.5921 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Tilray Brands Inc | 812.04m | -212.62m | 1.18bn | 2.65k | -- | 0.3297 | -- | 1.46 | -0.2746 | -0.2746 | 1.03 | 3.97 | 0.1875 | 2.31 | 8.73 | 306,429.10 | -4.64 | -- | -5.15 | -- | 29.42 | -- | -24.78 | -- | 1.57 | -1.16 | 0.0953 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Innoviva Inc | 352.75m | 64.59m | 1.19bn | 112.00 | 27.71 | 1.78 | 11.42 | 3.38 | 0.6879 | 0.6879 | 4.78 | 10.68 | 0.2916 | 1.14 | 4.44 | 3,149,509.00 | 5.34 | 26.24 | 5.98 | 28.53 | 87.93 | -- | 18.31 | 76.84 | 1.64 | 1.93 | 0.4011 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Ocular Therapeutix Inc | 61.44m | -174.34m | 1.33bn | 267.00 | -- | 3.79 | -- | 21.62 | -1.30 | -1.30 | 0.4442 | 2.25 | 0.1883 | 2.48 | 2.28 | 230,116.10 | -53.42 | -46.70 | -59.98 | -54.18 | 90.59 | 89.36 | -283.75 | -228.65 | 12.94 | -27.52 | 0.1615 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Harrow Inc | 169.14m | -33.41m | 1.56bn | 315.00 | -- | 26.95 | -- | 9.21 | -0.9408 | -0.9408 | 4.76 | 1.63 | 0.5305 | 4.86 | 4.69 | 536,946.10 | -10.48 | -10.86 | -12.74 | -12.71 | 72.56 | 70.75 | -19.75 | -15.35 | 1.44 | -0.3529 | 0.7635 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Immunocore Holdings PLC - ADR | 296.55m | -47.11m | 1.61bn | 497.00 | -- | 4.25 | -- | 5.42 | -0.9494 | -0.9494 | 5.88 | 7.55 | 0.3593 | 0.541 | 5.68 | 596,681.90 | -5.71 | -27.55 | -7.45 | -36.82 | 99.38 | -- | -15.89 | -97.12 | 3.76 | -- | 0.5373 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Tarsus Pharmaceuticals Inc | 129.62m | -134.34m | 1.77bn | 244.00 | -- | 7.46 | -- | 13.62 | -3.76 | -3.76 | 3.58 | 6.22 | 0.4022 | 6.37 | 7.51 | 531,233.60 | -41.68 | -31.56 | -48.37 | -33.82 | 92.97 | -- | -103.64 | -242.59 | 5.38 | -- | 0.2319 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Endo Inc | -100.00bn | -100.00bn | 1.87bn | 3.00k | -- | 1.02 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Harmony Biosciences Holdings Inc | 681.88m | 122.63m | 1.90bn | 246.00 | 15.73 | 3.18 | 12.90 | 2.78 | 2.11 | 2.11 | 11.75 | 10.46 | 0.7994 | 24.26 | 9.17 | 2,771,866.00 | 14.38 | 7.46 | 17.12 | 9.08 | 78.65 | 80.58 | 17.98 | 10.46 | 3.20 | -- | 0.2345 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Supernus Pharmaceuticals Inc | 651.97m | 59.71m | 1.98bn | 652.00 | 33.54 | 1.96 | 13.84 | 3.03 | 1.07 | 1.07 | 11.71 | 18.24 | 0.4962 | 0.9689 | 4.54 | 999,957.10 | 4.54 | 4.95 | 5.83 | 6.41 | 89.04 | 88.61 | 9.16 | 12.84 | 1.98 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Amphastar Pharmaceuticals Inc | 723.55m | 157.72m | 2.16bn | 1.76k | 14.82 | 2.96 | 10.21 | 2.98 | 3.01 | 3.01 | 13.79 | 15.04 | 0.4684 | 2.83 | 5.60 | 410,873.90 | 10.28 | 9.42 | 11.88 | 11.56 | 52.98 | 47.83 | 21.95 | 15.23 | 2.61 | 9.42 | 0.4506 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
Data as of Nov 22 2024. Currency figures normalised to Harrow Inc's reporting currency: US Dollar USD
37.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Opaleye Management, Inc.as of 30 Sep 2024 | 3.99m | 11.25% |
| Private Capital Management LLCas of 30 Sep 2024 | 2.16m | 6.10% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.07m | 5.83% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.78m | 5.02% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 730.97k | 2.06% |
| Geode Capital Management LLCas of 30 Sep 2024 | 722.73k | 2.04% |
| D. E. Shaw & Co. LPas of 30 Sep 2024 | 622.82k | 1.76% |
| Braidwell LPas of 30 Sep 2024 | 439.64k | 1.24% |
| Stifel Nicolaus & Co., Inc. (Investment Management)as of 30 Sep 2024 | 407.26k | 1.15% |
| Royce & Associates LPas of 30 Sep 2024 | 360.32k | 1.02% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
